# Sphere Fluidics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sphere-fluidics

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.spherefluidics.com
- Total disclosed funding: $24M
- Latest round: Series A (Oct 15, 2021)
- Investors on record: 2

## About

Sphere Fluidics Limited is a biotechnology company specializing in advanced single-cell analysis technologies, focused on enhancing antibody discovery and cell line development through innovative microfluidic solutions.Sphere Fluidics Limited, founded in 2010 in Cambridge, UK, develops single-cell analysis systems and has pivoted its offerings towards advanced microfluidic technologies. The company has successfully raised GBP 17.30 mn in its Series A funding round on October 15, 2021, co-led by Redmile Group and Sofinnova Partners. The total amount raised by the company is GBP 17.30 mn, with a current valuation of GBP 46.122 mn. The CEO of the company is Frank Craig and it was founded by Wilhelm Huck.Sphere Fluidics specializes in advanced single-cell analysis and isolation technologies, primarily utilizing their proprietary picodroplet microfluidic technology. Their core offerings include the Cyto-Mine® platform, which streamlines antibody discovery and cell line development processes, enabling researchers to identify high-producing, viable clones with increased efficiency and confidence. The company’s detection kits, such as the Cyto-Cellect® range, provide sensitive, animal-origin free assays for measuring cell clone productivity and detecting mouse IgG antibodies, catering to applications in biologics discovery, cell engineering, and synthetic biology. Sphere Fluidics' products are utilized by a diverse client base, including academic researchers, biopharmaceutical companies, and clinical laboratories, across key geographic markets including North America, Europe, and the Asia-Pacific region.Sphere Fluidics operates on a business-to-business model, generating revenue primarily through the sale of its Cyto-Mine® platform and associated reagents, consumables, and assay kits. The revenue model encompasses direct sales of products to research institutions and biopharmaceutical companies, as well as potential subscription-based support services that offer continued access to product updates and technical assistance. Transactions typically involve bulk purchases of consumables, with clients placing orders based on their specific project requirements. Flagship products such as the Cyto-Cellect® Human IgG Kappa and Viability Assay Kit are integral to their sales strategy, facilitating ongoing engagements with customers seeking to enhance their laboratory workflows and outcomes. Pricing structures vary by product category, reflecting the specialized nature of the technology and the value it delivers to the end users.Sphere Fluidics Limited plans to utilize the GBP 17.30 mn raised in its Series A funding round to expand its product research and development programs, focusing on novel applications for its proprietary Cyto-Mine® Single Cell Analysis System. The company is expected to design and launch new products targeting advancements in single-cell analysis, with plans to expand into new markets and geographic regions including Europe and the Asia-Pacific region in the near future.

## Funding rounds

- Series A, Oct 15, 2021, $24M — Sofinnova Partners, Redmile Group

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series A